Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2
出版年份 2022 全文链接
标题
Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2
作者
关键词
-
出版物
Microbiology Spectrum
Volume 10, Issue 5, Pages -
出版商
American Society for Microbiology
发表日期
2022-10-03
DOI
10.1128/spectrum.03331-22
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
- (2022) Pengfei Li et al. CELL RESEARCH
- Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2
- (2022) David C. Schultz et al. NATURE
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
- (2022) Jennifer Hammond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics
- (2022) Tom M. Quinn et al. EBioMedicine
- Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity
- (2022) Rachid Essalmani et al. JOURNAL OF VIROLOGY
- A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic
- (2022) Tirosh Shapira et al. NATURE
- SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples
- (2022) Aleksandr Ianevski et al. NUCLEIC ACIDS RESEARCH
- Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT)
- (2022) Florian Lemaitre et al. THERAPIE
- Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host
- (2022) Sissy Therese Sonnleitner et al. Nature Communications
- Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19
- (2022) Xiyuan Bai et al. Scientific Reports
- The Hypothiocyanite and Amantadine Combination Treatment Prevents Lethal Influenza A Virus Infection in Mice
- (2022) Nuha Milad Ashtiwi et al. Frontiers in Immunology
- Modeling explains prolonged SARS-CoV-2 nasal shedding relative to lung shedding in remdesivir treated rhesus macaques
- (2022) Ashish Goyal et al. iScience
- In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance
- (2022) Liva Checkmahomed et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- From Positive to Negative to Positive Again—The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid
- (2022) Rita Rubin JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model
- (2022) Paulina Koszalka et al. mBio
- Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms
- (2022) Julia M Flynn et al. eLife
- The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro
- (2022) Anna Gidari et al. Microorganisms
- Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs
- (2021) Shawn Herring et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Treatment failure with DAA therapy: importance of resistance
- (2021) Christoph Sarrazin JOURNAL OF HEPATOLOGY
- Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2
- (2021) Sabari Nath Neerukonda et al. PLoS One
- Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo
- (2021) Courtney L. Finch et al. Microorganisms
- Synergistic block of SARS-CoV-2 infection by combined drug inhibition of the host entry factors PIKfyve kinase and TMPRSS2 protease
- (2021) Alex J.B. Kreutzberger et al. JOURNAL OF VIROLOGY
- Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
- (2021) Florence Ader et al. LANCET INFECTIOUS DISEASES
- Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
- (2021) Meagan P. O’Brien et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Variants in Patients with Immunosuppression
- (2021) Lawrence Corey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiviral Activity of Umifenovir In Vitro against a Broad Spectrum of Coronaviruses, Including the Novel SARS-CoV-2 Virus
- (2021) Irina Leneva et al. Viruses-Basel
- Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2
- (2021) Aleksandr Ianevski et al. Viruses-Basel
- The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19
- (2021) Kun Li et al. mBio
- Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
- (2021) David R. Martinez et al. Cell Reports
- In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2
- (2021) Agnieszka M. Szemiel et al. PLoS Pathogens
- The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
- (2021) Markus Hoffmann et al. CELL
- Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
- (2021) Robert L. Gottlieb et al. NEW ENGLAND JOURNAL OF MEDICINE
- A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells
- (2021) Matthew Mahoney et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
- (2021) Dafydd R. Owen et al. SCIENCE
- A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
- (2021) William A. Fischer et al. Science Translational Medicine
- Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
- (2021) Judith M. White et al. mBio
- Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants
- (2021) Sebastian Weigang et al. Nature Communications
- Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports
- (2021) Elisabeth Mahase BMJ-British Medical Journal
- Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports
- (2021) Elisabeth Mahase BMJ-British Medical Journal
- SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy
- (2020) Aleksandr Ianevski et al. PLoS Computational Biology
- Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
- (2020) Markus Hoffmann et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
- (2020) Timothy P. Sheahan et al. Science Translational Medicine
- The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
- (2020) Xi Wang et al. Cell Discovery
- Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial
- (2020) Michael G Ison et al. LANCET INFECTIOUS DISEASES
- Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
- (2020) Laura Riva et al. NATURE
- An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2
- (2020) Joshua T Schiffer et al. Open Forum Infectious Diseases
- Identification and Tracking of Antiviral Drug Combinations
- (2020) Aleksandr Ianevski et al. Viruses-Basel
- Synergistic and Antagonistic Drug Combinations against SARS-CoV-2
- (2020) Tesia Bobrowski et al. MOLECULAR THERAPY
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
- (2020) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
- (2019) Sabue Mulangu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures
- (2018) Julie Dyall et al. JOURNAL OF INFECTIOUS DISEASES
- Diagonal Method to Measure Synergy Among Any Number of Drugs
- (2018) Melike Cokol-Cakmak et al. Jove-Journal of Visualized Experiments
- Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects
- (2017) Elena Bekerman et al. JOURNAL OF CLINICAL INVESTIGATION
- Current status and prospects of HIV treatment
- (2016) Tomas Cihlar et al. Current Opinion in Virology
- Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- A quantitative basis for antiretroviral therapy for HIV-1 infection
- (2012) Benjamin L Jilek et al. NATURE MEDICINE
- Triple Combination of Amantadine, Ribavirin, and Oseltamivir Is Highly Active and Synergistic against Drug Resistant Influenza Virus Strains In Vitro
- (2010) Jack T. Nguyen et al. PLoS One
- Triple Combination of Oseltamivir, Amantadine, and Ribavirin Displays Synergistic Activity against Multiple Influenza Virus Strains In Vitro
- (2009) J. T. Nguyen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started